CurrentCapital BluecrossPolicy MP 2.222

Serum Antibody Markers for Diagnosing and Monitoring Inflammatory Bowel Disease

Capital Blue Cross medical policy MP 2.222 addresses the use of serum antibody markers (ANCA, ASCA) and related commercial panels (eg, Prometheus IBD sgi Diagnostic, Crohn's Prognostic) for the diagnosis and monitoring of inflammatory bowel disease (IBD). The policy states these tests are investigational and not covered due to insufficient evidence of clinical utility.

Policy Summary

PayerCapital Bluecross

PolicySerum Antibody Markers for Diagnosing and Monitoring Inflammatory Bowel Disease

Policy CodePolicy MP 2.222

Change TypeAdministrative / Consensus reviews (no material clinical change)

Effective Date11/01/2025

Next Review Date

Key ActionProviders should not rely on ANCA or ASCA testing as a substitute for standard radiographic, endoscopic, and histologic diagnostic workup for IBD because the policy deems these assays investigational and not covered.

SourceLink

POLICY UPDATE CHANGES

10/08/2025 Administrative Update: Removed Benefit Variations Section and updated Disclaimer.

07/09/2025 Consensus review. No change to policy intent. Updated references. Coding review. No changes.

01/19/2024 Administrative Update. Clinical benefit added.

09/06/2023 Consensus Review. Changed title to include 'monitoring'. Added Prometheus Crohn's Prognostic test information to background and associated codes to coding table.

03/11/2022 Consensus Review. Added codes 86036 and 86037. Removed 86140. No change to policy statement.

01/05/2021 Consensus Review. Updated background with most current Prometheus test. References updated. Coding reviewed. Added codes 81479, 82397, 83516, 83520, 86021, 86140, 86671, 88346, and 88350.

01/23/2020 Consensus Review. No change to policy statements. References updated. Coding reviewed.

Coverage Summary

Policy stance: Investigational / Not covered — Determination of ANCA and ASCA and related commercial panels is considered investigational and there is insufficient evidence that these tests improve patient-important health outcomes.

See the Medical-Necessity Criteria section for the full determinative language and the specific policy statement regarding investigational status and coverage implications.

Policy metadata

Policy numberMP 2.222

Policy stanceInvestigational

Effective date11/01/2025

Last review07/09/2025

SubjectSerum antibody markers (ANCA, ASCA, Prometheus panels) for diagnosing and monitoring inflammatory bowel disease

Medical-Necessity / Investigational Determination

Medically Necessary / Investigational Determination

Policy statement:

ALL of the following

Determination of anti-neutrophil cytoplasmic antibody (ANCA) and anti-Saccharomyces cerevisiae antibody (ASCA) is considered investigational in the workup and monitoring of patients with inflammatory bowel disease.
There is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with these procedures.

ref

Not Covered — Investigational Tests

ANCA, ASCA, and Prometheus commercial panels (eg, Prometheus IBD sgi Diagnostic, Crohn's Prognostic) are considered investigational and not covered because the clinical utility of these assays has not been demonstrated to change patient-important outcomes.

Prometheus commercial panels combine serologic, genetic, and inflammation markers (for example, the IBD sgi Diagnostic uses 17 assay results and the Crohn's Prognostic panel includes serologic and genetic markers) but studies and systematic reviews have not shown these tests alter the standard diagnostic workup or reduce invasive testing.

Investigational; therefore, not coveredCPTNot Covered

86037
81479
81599
86255
86671
82397
88346
83516
88350
83520

1–10 of 13

1/2

Provider Actions & Billing Impact

Documentation Required

Do not substitute standard workup with antibody tests

Providers should not rely on ANCA or ASCA testing as a substitute for standard radiographic, endoscopic, and histologic diagnostic workup for IBD because the policy deems these assays investigational and not covered.

Billing Rule

Claims for investigational tests may be denied

Tests listed as investigational (codes in coding table) are not covered; payment of claims is subject to member benefits and medical necessity determinations and may be denied.

86037
81479
81599
86255
86671

Background & Evidence

ANCA (anti‑neutrophil cytoplasmic antibody) and ASCA (anti‑Saccharomyces cerevisiae antibody) are serum antibodies that have been studied for diagnostic and prognostic uses in IBD — including differentiating ulcerative colitis from Crohn disease, classifying disease subtypes by location or severity, and potentially predicting response to therapy.

Prometheus commercial panels (eg, PROMETHEUS® IBD sgi Diagnostic™ and Crohn's Prognostic) combine serologic, genetic, and inflammation markers (the IBD sgi Diagnostic assesses multiple proprietary serologic biomarkers and pattern recognition across 17 assay results; the Crohn's Prognostic panel includes serologic and genetic markers such as ASCA IgA/IgG and NOD2 variants). However, systematic reviews report relatively low sensitivity and only moderate specificity for these serologic markers, and the clinical utility of these assays has not been demonstrated — no studies have shown they can replace the standard radiographic, endoscopic, and histologic diagnostic workup or improve net health outcomes.

Evidence Type	Summary
Systematic reviews
Found relatively low sensitivity and moderately high specificity; clinical utility not demonstrated
Regulatory status
Serum testing for ANCA and ASCA does not require FDA approval
Background - Prometheus panels
Prometheus panels (IBD sgi Diagnostic, Crohn's Prognostic) combine serologic, genetic, and inflammation markers; clinical utility for changing patient-important outcomes not demonstrated

ANCA — Anti‑neutrophil cytoplasmic antibody

ASCA — Anti‑Saccharomyces cerevisiae antibody

Prometheus IBD sgi Diagnostic / Crohn's Prognostic — Commercial panels combining serologic, genetic, and inflammation markers to aid IBD diagnosis or prognostication

Revision History

10/08/2025revisedLatest

10/08/2025 Administrative Update: Removed Benefit Variations Section and updated Disclaimer.

07/09/2025revised

07/09/2025 Consensus review. No change to policy intent. Updated references. Coding review. No changes.

01/19/2024revised

01/19/2024 Administrative Update. Clinical benefit added.